[{"data":1,"prerenderedAt":228},["ShallowReactive",2],{"$f1jxpreqqwdjjm":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":23,"top_modalities":55,"top_diseases":85,"top_companies":114,"key_results":144,"trends":216,"previous_editions":225,"comparison":181,"highlighted_classes":226},1,"euretina-2026","EURETINA","euretina","EURETINA Congress 2026",2026,"Ophthalmology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},1974,758,86,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":20,"Phase 2\u002F3":21,"Phase 3":22},16,12,24,8,6,50,[24,28,32,36,39,43,46,48,50,53],{"name":25,"count":26,"share":27},"VEGFA",348,46,{"name":29,"count":30,"share":31},"ANGPT2",148,20,{"name":33,"count":34,"share":35},"VEGFB",139,18,{"name":37,"count":38,"share":35},"PGF",138,{"name":40,"count":41,"share":42},"GR",108,14,{"name":44,"count":18,"share":45},"DHFR",2,{"name":47,"count":18,"share":45},"Neuraminidase",{"name":49,"count":18,"share":45},"PLG",{"name":51,"count":52,"share":4},"TNFA",11,{"name":54,"count":52,"share":4},"VEGFR",[56,60,64,68,72,75,79,82],{"name":57,"count":58,"share":59},"Small molecules",312,41,{"name":61,"count":62,"share":63},"Monoclonal antibodies",268,35,{"name":65,"count":66,"share":67},"Non-antibody therapeutic proteins",210,28,{"name":69,"count":70,"share":71},"Bispecific antibodies",166,22,{"name":73,"count":63,"share":74},"Carbohydrate, lipid and polymer therapeutics",5,{"name":76,"count":77,"share":78},"Gene therapies",31,4,{"name":80,"count":81,"share":45},"Non-radioactive imaging and contrast agents",17,{"name":83,"count":84,"share":45},"Blood, tissue and cell-derived products",15,[86,90,94,97,100,102,105,107,110,112],{"name":87,"count":88,"share":89},"exudative macular degeneration",201,27,{"name":91,"count":92,"share":93},"diabetic macular edema (DME)",171,23,{"name":95,"count":96,"share":20},"macular edema",64,{"name":98,"count":99,"share":20},"Vein occlusion (RVO)",59,{"name":101,"count":59,"share":74},"age-related macular degeneration (AMD)",{"name":103,"count":104,"share":74},"retinal detachment",38,{"name":106,"count":104,"share":74},"uveitis",{"name":108,"count":109,"share":78},"central retinal vein occlusion (CRVO)",29,{"name":111,"count":67,"share":78},"branch retinal vein occlusion (BRVO)",{"name":113,"count":89,"share":78},"cystoid macular edema (CME)",[115,119,122,125,129,132,135,137,139,142],{"name":116,"count":117,"share":118},"Roche",161,21,{"name":120,"count":121,"share":81},"Regeneron Pharmaceuticals",132,{"name":123,"count":124,"share":20},"Genentech",57,{"name":126,"count":127,"share":128},"Merck",52,7,{"name":130,"count":131,"share":78},"Pfizer",33,{"name":133,"count":19,"share":134},"Medline Industries",3,{"name":136,"count":84,"share":45},"GSK",{"name":138,"count":42,"share":45},"Sanofi",{"name":140,"count":141,"share":45},"AbbVie",13,{"name":143,"count":52,"share":4},"Bristol Myers Squibb",[145,155,164,171,177,185,192,200,207],{"title":146,"drug":147,"company":150,"phase":151,"disease":152,"finding":153,"url":154},"Neuroprotective Effect of Revakinagene Taroretcel-lwey on Central Macular Function in Macular Telangiectasia Type 2",{"name":148,"slug":149},"revakinagene taroretcel-lwey","revakinagene-taroretcel-lwey","Neurotech","Phase 3","macular telangiectasia type 2 (MacTel)","Functional stability was observed nearly twice as frequently in the treatment group (21\u002F108 [19.4%] eyes) compared with the sham group (10\u002F103 [9.7%] eyes), representing a more than twofold increase in the odds of a stable outcome (odds ratio: 2.24; 95% CI: 0.94–5.64; P=0.053).","https:\u002F\u002Fhub-distribution.euretina.org\u002Ffrom.storage?image=tGNQYSthhlBqu33Y-T107aILTWTRogUisEXyllA-9AP_88XZ1PTYs4BBU3vBHaC_0",{"title":156,"drug":157,"company":160,"phase":151,"disease":161,"finding":162,"url":163},"Intravitreal Tarcocimab Tedromer for Diabetic Retinopathy: Cross-trial Evaluation of the Phase 3 GLOW and GLOW2 Studies",{"name":158,"slug":159},"tarcocimab tedromer","tarcocimab-tedromer","Kodiak Biosciences","diabetic retinopathy (DR)","Tarcocimab met the primary endpoint, with a ≥2-step DRSS improvement observed in 41.1% of tarcocimab-treated eyes compared with 1.4% of sham-treated eyes, representing a 29-fold higher response rate with tarcocimab (p\u003C0.0001).","https:\u002F\u002Fhub-distribution.euretina.org\u002Ffrom.storage?image=tGNQYSthhlBqu33Y-T107XfNYl3UeZdkEiZYHh9J44Lb80fBkkfVW9LoBTZMZ6aD0",{"title":165,"drug":166,"company":116,"phase":151,"disease":168,"finding":169,"url":170},"Efficacy and Safety of Vamikibart in Patients With Uveitic Macular Edema: Pooled Results from the Phase 3 MEERKAT and SANDCAT Trials",{"name":167,"slug":167},"vamikibart","uveitic macular edema (UME)","Adjusted proportion of patients with ≥15-letter improvement in BCVA for pooled MK\u002FSC: 30.2% 0.25 mg, 33.3% 1.0 mg vamikibart vs 9.9% sham.","https:\u002F\u002Fhub-distribution.euretina.org\u002Ffrom.storage?image=tGNQYSthhlBqu33Y-T107ZRnt7-4ZwyS2zVJ5lUwn7SQ271L0FFRga2jyeqlQAtT0",{"title":172,"drug":173,"company":123,"phase":151,"disease":161,"finding":175,"url":176},"Low Risk of Proliferative Vision-Threatening Complications Observed in Patients with Diabetic Eye Disease Treated with Continuous Delivery via the Port Delivery Platform with Ranibizumab (PDS)",{"name":174,"slug":174},"ranibizumab","Through W112, 56.3% and 27.6% from PDS Q24W achieved ≥2-step and ≥3-step DRSS improvement compared with 52.1% and 23.9% in IVT-PDS Q24W.","https:\u002F\u002Fhub-distribution.euretina.org\u002Ffrom.storage?image=tGNQYSthhlBqu33Y-T107RB6oLcYGVLPMEghyYjelCyxFSp-s_zaVS8cX9W9ZPR90",{"title":178,"drug":179,"company":181,"phase":151,"disease":182,"finding":183,"url":184},"Paired-eye post hoc analysis of the ILLUMINATE trial demonstrates 12-month functional improvements with sepofarsen in CEP290-associated retinal dystrophy",{"name":180,"slug":180},"sepofarsen",null,"Leber congenital amaurosis (LCA)","For BCVA (ETDRS\u002FBRVT), mean improvements in TEs reached –0.17 logMAR at Month 6 and –0.20 logMAR at Months 9 and 12, compared with minimal change in CEs (between 0.02 and −0.03 logMAR), with statistically significant differences TE vs CE at Months 6, 9, and 12 (p≤0.01).","https:\u002F\u002Fhub-distribution.euretina.org\u002Ffrom.storage?image=tGNQYSthhlBqu33Y-T107aROfn4hHKavkkgBdpp3eYNz97A57SQGTvJlztDe2pMb0",{"title":186,"drug":187,"company":181,"phase":189,"disease":87,"finding":190,"url":191},"Comparable Safety Profile with Aflibercept 8 mg versus 2 mg: A Pooled Safety Analysis of the CANDELA, PULSAR, PHOTON, and QUASAR Trials",{"name":188,"slug":188},"aflibercept","Phase 2\u002F3","The incidence of IOP- and glaucoma-related TEAEs in the study eye was 5.6% and 4.3% in the pooled aflibercept 8 mg and 2 mg groups, respectively.","https:\u002F\u002Fhub-distribution.euretina.org\u002Ffrom.storage?image=tGNQYSthhlBqu33Y-T107dr8NWZKA7N5jvBEmvFpHxe5VThV7iSDS8QEuQoP-SFH0",{"title":193,"drug":194,"company":197,"phase":189,"disease":91,"finding":198,"url":199},"Bioerodible EYP-1901 (vorolanib intravitreal insert) for Diabetic Macular Edema: From the Phase 2 VERONA Trial to Pivotal Phase 3 COMO and CAPRI Trials",{"name":195,"slug":195,"named_as":196},"vorolanib","EYP-1901","EyePoint Pharmaceuticals","At W24, mean BCVA change from baseline was +7.1, +6.9, and +7.3 letters with EYP-1901 2.7 mg, EYP-1901 1.3 mg, and aflibercept, respectively.","https:\u002F\u002Fhub-distribution.euretina.org\u002Ffrom.storage?image=tGNQYSthhlBqu33Y-T107ZPPt1phHwyoPs7zDTFmSb_syVHmiTWwN-Zsascy6Qn70",{"title":201,"drug":202,"company":181,"phase":204,"disease":87,"finding":205,"url":206},"One-Year Prospective Single-Arm Clinical Trial of Switching to Faricimab in Previously Treated Neovascular Age-Related Macular Degeneration With Inadequate Response: The FURGGHORN Study.",{"name":203,"slug":203},"faricimab","Phase 4","At week 52 after switching to faricimab, mean BCVA change was +0.9 letters (95%CI: -0.5 to 2.4, P=0.069), mean CST change was -74.7 µm (95%CI: -95.0 to -54.5, P\u003C0.001), and mean PED height change was -72.5 µm (95%CI: -98.4 to -46.7, P\u003C0.001).","https:\u002F\u002Fhub-distribution.euretina.org\u002Ffrom.storage?image=tGNQYSthhlBqu33Y-T107ZKQfjoyMhGTwPCPMVW6GWBrEPLPtKIT2bRFx1F6Jv4q0",{"title":208,"drug":209,"company":212,"phase":213,"disease":87,"finding":214,"url":215},"Efficacy and Safety of a Novel Topical Peptide (CG-P5) for the Treatment of Neovascular Age-Related Macular Degeneration: Phase 1 Results",{"name":210,"slug":211},"CG-P5 peptide","cg-p5-peptide","Caregen","Phase 1","At Day 56, CG-P5 achieved an IRF-free responder rate of 83.3%, compared to 25.0% for placebo and 60.0% for Eylea.","https:\u002F\u002Fhub-distribution.euretina.org\u002Ffrom.storage?image=tGNQYSthhlBqu33Y-T107ZE4RMdi_i7irhMYC0cAtNNCY5hhqL1rzipoRd4LuXDY0",{"summary":217,"bullets":219},[218],"Small molecules were the most frequent modality (41% of drug-linked abstracts). VEGFA was the most frequent target (46%). Exudative macular degeneration was the most frequent disease (27%).",[220,221,222,223,224],"Roche had the largest company share (21% of drug-linked abstracts).","Bispecific antibodies accounted for 22% of drug-linked abstracts.","Monoclonal antibodies were the next most frequent modality (35%).","ANGPT2 was the next most frequent target (20%).","Diabetic macular edema (DME) was the next most frequent disease (23%).",[],[227],{"name":69,"count":70,"share":71,"previous_count":181,"previous_share":181,"direction":181},1793970603102]